6 Endocrinology Headlines You Missed in January 2026

During January, endocrinology saw a slew of medical and technological approvals and advancements. The US Food and Drug Administration (FDA) cleared the MiniMed Go Smart Multiple Daily Injection (MDI) app for patients ≥7 years with type 1 diabetes (T1D) or type 2 diabetes (T2D), as well as approving an updated starting dose guideline for inhaled insulin powder in T1D. Diabeloop received clearance for its DBLG2 algorithm and has since partnered with Sequel Med Tech to integrate the program with the Twiist automated insulin delivery system.